Goh George Boon-Bee, McCullough Arthur J
Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore.
Duke-NUS Graduate Medical School, Singapore, Singapore.
Dig Dis Sci. 2016 May;61(5):1226-33. doi: 10.1007/s10620-016-4095-4. Epub 2016 Mar 22.
Nonalcoholic fatty liver disease (NAFLD) remains among the most common liver diseases worldwide, with increasing prevalence in concert with the obesity and metabolic syndrome epidemic. The evidence on the natural history, albeit with some ambiguity, suggests the potential for some subsets of NAFLD to progress to cirrhosis, liver-related complications and mortality with fibrosis being the most important predictor of hard long-term endpoints such as mortality and liver complications. In this setting, NAFLD proves to be a formidable disease entity, with considerable clinical burden, for both the present and the future. Our understanding of the natural history of NAFLD is constantly evolving, with nascent data challenging current dogma. Further clarification of the natural history is required with well-designed, well-defined studies using prospectively collected data. Identifying the predictors of long-term outcomes should be used to direct development of clinical trial endpoints in NAFLD.
非酒精性脂肪性肝病(NAFLD)仍然是全球最常见的肝脏疾病之一,其患病率随着肥胖和代谢综合征的流行而不断上升。尽管存在一些不确定性,但关于自然史的证据表明,NAFLD的某些亚组有可能进展为肝硬化、肝脏相关并发症和死亡,纤维化是死亡率和肝脏并发症等严重长期终点的最重要预测因素。在这种情况下,NAFLD被证明是一个 formidable 的疾病实体,无论是现在还是未来,都具有相当大的临床负担。我们对NAFLD自然史的理解在不断发展,新出现的数据对当前的教条提出了挑战。需要通过精心设计、明确界定的研究,使用前瞻性收集的数据,进一步阐明其自然史。确定长期结局的预测因素应被用于指导NAFLD临床试验终点的制定。